Xu Donghan, Luo Yehao, Wang Peng, Li Jiaxin, Ma Linrui, Huang Jie, Zhang Hao, Yang Xiaoman, Li Liqi, Zheng Yuhong, Fang Gang, Yan Peiyu
Faculty of Chinese Medicine, Macau University of Science and Technology, Macao, Macao SAR, China.
School of Second Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Front Oncol. 2023 Jun 12;13:1148131. doi: 10.3389/fonc.2023.1148131. eCollection 2023.
The incidence of gastric cancer is increasing year by year. Most gastric cancers are already in the advanced stage with poor prognosis when diagnosed, which means the current treatment is not satisfactory. Angiogenesis is an important link in the occurrence and development of tumors, and there are multiple anti-angiogenesis targeted therapies. To comprehensively evaluate the efficacy and safety of anti-angiogenic targeted drugs alone and in combination against gastric cancer, we systematically searched and sorted out relevant literature. In this review, we summarized the efficacy and safety of Ramucirumab, Bevacizumab, Apatinib, Fruquintinib, Sorafenib, Sunitinib, Pazopanib on gastric cancer when used alone or in combination based on prospective clinical trials reported in the literature, and sorted response biomarkers. We also summarized the challenges faced by anti-angiogenesis therapy for gastric cancer and available solutions. Finally, the characteristics of the current clinical research are summarized and suggestions and prospects are raised. This review will serve as a good reference for the clinical research of anti-angiogenic targeted drugs in the treatment of gastric cancer.
胃癌的发病率逐年上升。大多数胃癌在确诊时已处于晚期，预后较差，这意味着目前的治疗效果并不理想。血管生成是肿瘤发生发展的重要环节，存在多种抗血管生成靶向治疗方法。为全面评估抗血管生成靶向药物单药及联合治疗胃癌的疗效和安全性，我们系统检索并整理了相关文献。在本综述中，我们基于文献报道的前瞻性临床试验，总结了雷莫西尤单抗、贝伐单抗、阿帕替尼、呋喹替尼、索拉非尼、舒尼替尼、帕唑帕尼单药或联合使用时对胃癌的疗效和安全性，并梳理了反应生物标志物。我们还总结了胃癌抗血管生成治疗面临的挑战及可用解决方案。最后，总结了当前临床研究的特点并提出建议和展望。本综述将为抗血管生成靶向药物治疗胃癌的临床研究提供良好参考。
